International Journal of Clinical Oncology最新文献

{"title":"Safety and efficacy of neoadjuvant S-1 and oxaliplatin therapy for gastric cancer in the elderly: combined phase II trials of KSCC1601 and KSCC1801.","authors":"Keiichiro Ryujin, Kojiro Shirabe, Shota Sato, Akihiko Otake, Yuki Shin, Keita Natsugoe, Tetsuro Kawazoe, Sho Nambara, Yasuo Tsuda, Tomonori Nakanoko, Koji Ando, Mitsuhiko Ota, Masaaki Iwatsuki, Hiroshi Saeki, Tomoharu Yoshizumi, Eiji Oki","doi":"10.1007/s10147-026-03204-x","DOIUrl":"https://doi.org/10.1007/s10147-026-03204-x","url":null,"abstract":"<p><strong>Background: </strong>The efficacy of neoadjuvant chemotherapy in elderly patients with locally advanced gastric cancer remains unclear. We evaluated neoadjuvant S-1 plus oxaliplatin (SOX) therapy in elderly patients using patient data from two phase II trials.</p><p><strong>Methods: </strong>Patient data from KSCC1601 and KSCC1801 phase II trials were integrated. Patients were divided into an elderly group (age ≥75 years) and a non-elderly group (age <75 years). Adverse events, postoperative complications, and outcomes were compared. Overall survival (OS) and recurrence-free survival (RFS) were calculated from treatment initiation.</p><p><strong>Results: </strong>Among the 73 patients enrolled in trials, 66 (90.4%) underwent surgery and 65 (89.0%) achieved R0 resection. Neoadjuvant SOX therapy was administered to 69 patients (94.5%). Among those with R0 resection, 22 were aged ≥75 years and 43 were aged <75 years. PS 1 was significantly more common in the elderly group, with no other baseline differences. Postoperative complications developed in 11 patients (16.9%), including 1 (4.5%) in the elderly group and 10 (23.3%) in the non-elderly group (p = 0.12). Grade III or higher complications occurred only in the non-elderly group. OS and RFS did not differ significantly between the age groups (OS: Hazard ratio (HR) = 0.78, 95% Confidence Interval (CI) 0.27-2.21, p = 0.64; RFS: HR = 1.12, 95% CI 0.51-2.44, p = 0.79). Undifferentiated histology, stage III disease, and poor pathological response were associated with worse survival.</p><p><strong>Conclusions: </strong>Neoadjuvant SOX therapy is feasible in selected elderly patients with locally advanced gastric cancer and yields survival comparable to those of younger patients.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective study evaluating the impact of waiting time on blood testing and clinical workflows in cancer patients.","authors":"Yu Sunakawa, Hiroyuki Arai, Yohei Kubota, Yusuke Nagata, Hiroyuki Takeda, Kumiko Umemoto, Yoshiki Horie, Naoki Izawa, Takashi Ogura, Kiyoshi Okazuka, Yuta Okamura, Toshihide Hosoyamada, Yumi Izumaru, Yukiko Sakakibara, Junpei Soeda, Reo Takaku","doi":"10.1007/s10147-026-03197-7","DOIUrl":"https://doi.org/10.1007/s10147-026-03197-7","url":null,"abstract":"<p><strong>Background: </strong>Long waiting times on chemotherapy days increase patient burden. Pre-visit blood sampling may streamline workflows; however, its real-world impact remains unclear.</p><p><strong>Methods: </strong>This prospective study collected data on waiting times for pre-visit vs same-day blood sampling in 50 cancer patients receiving chemotherapy between October 2024 and February 2025 at St. Marianna University Hospital. Pre‑visit and same‑day blood sampling was compared in the same patients across four waiting times: (i) check-in to consultation, (ii) check-in to check-out, and (iii-iv) extended measures incorporating travel time. For times (iii) and (iv), travel time during pre-visit was also included. Patient and physician satisfaction and indirect costs were also evaluated.</p><p><strong>Results: </strong>The median waiting time from check-in to consultation was 1.8 and 2.2 h for pre-visit and same-day sampling, respectively; when chemotherapy and check-out were included (ii), total duration was similar (6.3 vs 6.3 h). Extended measures (iii-iv) tended to be longer with pre-visit sampling. After excluding the two outliers, waiting time from check-in to chemotherapy was significantly shorter for pre-visit vs same-day sampling (3.3 vs 3.9 h, p=0.025). Patient satisfaction was favorable, and 24.0% of patients reported reduced burden. Indirect costs improved by approximately 1198 Japanese yen per patient, with benefits reported in approximately half of the cases. Subgroup analyses suggested greater benefits for patients living within 30 min of both pre-visit blood sampling and chemotherapy facilities.</p><p><strong>Conclusions: </strong>Pre-visit blood sampling may reduce waiting time and perceived burden for selected patients, although overall time savings were modest. Trial registration University Hospital Medical Information Network (UMIN) Clinical Trials Registry: UMIN000055757.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: second recurrence after R0 resection of recurrent colorectal cancer: patterns and implications for surveillance.","authors":"Min Zou, Zijie Yang, Feng Gao, Zengqiang Yang","doi":"10.1007/s10147-026-03216-7","DOIUrl":"https://doi.org/10.1007/s10147-026-03216-7","url":null,"abstract":"","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of lisocabtagene maraleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: 31-month follow-up of the phase 2 TRANSCEND FL study.","authors":"Shinichi Makita, Hideki Goto, Koji Izutsu, Yuichi Baba, Merav Bar, Maria Strocchia, Prachi Ghodke, Rina Nishii, Takanori Teshima","doi":"10.1007/s10147-026-03199-5","DOIUrl":"https://doi.org/10.1007/s10147-026-03199-5","url":null,"abstract":"<p><strong>Background: </strong>Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor T-cell therapy, showed high response rates and favorable safety in patients with relapsed/refractory (R/R) FL in the international, pivotal, phase 2 study (TRANSCEND FL). We report results from TRANSCEND FL in Japanese patients with second-line or later (2L+) FL after a median on-study follow-up of 31 months.</p><p><strong>Methods: </strong>Key eligibility criteria were age ≥18 years, prior combination systemic therapy including an anti-CD20 antibody and alkylating agent, and positron emission tomography-positive, measurable lesions. Primary endpoint was overall response rate (ORR) per independent review committee using Lugano 2014 criteria. Secondary endpoints included complete response (CR) rate, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.</p><p><strong>Results: </strong>Overall, 10 Japanese patients received liso-cel and were evaluated for safety; 9 were efficacy-evaluable. Patients had a median age of 67 years and a median of 3 prior systemic therapies. ORR and CR rate (95% CI) were both 100% (66.4-100). Median DOR and PFS were not reached, 24-month DOR and PFS rates (95% CI) were both 88.9% (43.3-98.4), and only 1 patient had relapsed. All patients were alive at data cutoff. Rates of any-grade cytokine release syndrome (CRS), neurological events (NEs), and infections were 30%, 10%, and 30%, respectively; no grade ≥3 CRS, NEs, or infections were reported. No new safety signals were detected.</p><p><strong>Conclusions: </strong>These data underscore liso-cel as an effective treatment option with a manageable safety profile for Japanese patients with 2L+ R/R FL. Trial registration number NCT04245839.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between fat-free mass index and severe locomotive syndrome in patients with cancer: sex-specific cutoff values.","authors":"Ryoga Kashima, Ryo Yoshikawa, Wataru Saho, Yasumitsu Fujii, Risa Harada, Junichiro Inoue, Daisuke Makiura, Katsuya Fujiwara, Mayu Mizuta, Yoshitada Sakai","doi":"10.1007/s10147-026-03217-6","DOIUrl":"https://doi.org/10.1007/s10147-026-03217-6","url":null,"abstract":"<p><strong>Background: </strong>Locomotive syndrome (LS) is a clinical condition used to describe reduced mobility caused by musculoskeletal dysfunction and is highly prevalent among patients with cancer. The fat-free mass index (FFMI) is an indicator of nutritional status and muscle mass, and has been associated with malnutrition and prognosis in this population. This study investigated the relationship between FFMI and LS in patients with cancer and determined sex-specific FFMI cutoff values associated with severe LS.</p><p><strong>Methods: </strong>This study included patients hospitalized for cancer treatment who were referred for rehabilitation therapy. Patient characteristics, laboratory data, body composition, and grip strength were collected. LS was assessed using the stand-up test, two-step test, and 25-Geriatric Locomotive Function Scale. FFMI was measured using bioelectrical impedance analysis.</p><p><strong>Results: </strong>Overall, 144 patients (102 men and 42 women; mean age, 63.9 ± 15.8 years) were analyzed. Ordinal logistic regression analysis demonstrated that FFMI was independently associated with LS severity (odds ratio [OR], 0.597; 95% confidence interval [CI], 0.434-0.821). The optimal FFMI cutoff values associated with severe LS (grade ≥ 2) were 16.99 kg/m² in men and 15.25 kg/m² in women, with areas under the curves of 0.806 (95% CI, 0.720-0.890) and 0.760 (95% CI, 0.596-0.925), respectively.</p><p><strong>Conclusions: </strong>FFMI was associated with mobility function in patients with cancer. The proposed sex-specific cutoff values may help identify patients with impaired mobility who could be considered for referral to rehabilitation therapy.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between tumor volume reduction and treatment outcomes in nasopharyngeal carcinoma treated with PCE-based induction chemotherapy and concurrent chemoradiotherapy.","authors":"Ya Guo, Satoshi Saito, Kenji Makita, Tomohiro Enokida, Takashi Hiyama, Ryo Kuboki, Hirofumi Kuno, Masaki Nakamura, Yuichi Hiroshima, Hidenari Hirata, Masashi Wakabayashi, Yunhao Zhang, Nobukazu Tanaka, Makoto Tahara, Sadamoto Zenda","doi":"10.1007/s10147-026-03212-x","DOIUrl":"https://doi.org/10.1007/s10147-026-03212-x","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the association between total tumor volume reduction rate (VRR) and treatment outcomes in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) treated with paclitaxel, carboplatin, and cetuximab (PCE)-based induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT).</p><p><strong>Methods: </strong>Patients with LA-NPC who were planned to undergo IC-PCE followed by CCRT between September 2017 and December 2024 were included. Overall survival (OS) and progression-free survival (PFS) were calculated, and factors associated with PFS were evaluated. VRR was dichotomized based on a cutoff value derived from receiver operating characteristic curve analysis.</p><p><strong>Results: </strong>In total, 43 consecutive patients with LA-NPC (median age, 56 years) were included. The median follow-up time was 48 months (Interquartile Range, 34-69). The 3-year OS and PFS were 95.3% and 76.1%, respectively. A total of 12 PFS events were observed, including locoregional recurrence (n = 3), distant metastasis (n = 6), both (n = 1), and death (n = 2). In multivariable analysis adjusted for cStage (Union for International Cancer Control 9th edition), a high VRR (cutoff value, 48.6%) was identified as a significant factor associated with improved PFS (hazard ratio, 0.21; 95% confidence interval, 0.06-0.70; p = 0.01).</p><p><strong>Conclusion: </strong>VRR was associated with PFS, suggesting that tumor shrinkage following IC-PCE may serve as a prognostic marker.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy and safety of second-line cabozantinib after first-line immune checkpoint inhibitor-based combinations in metastatic renal cell carcinoma: a multicenter retrospective study.","authors":"Atsuki Matsukawa, Taigo Kato, Masaharu Oki, Tetsuya Takao, Lan Inoki, Mototaka Sato, Koichi Okada, Takahiro Maekawa, Takahiro Imanaka, Jiro Nakayama, Eisuke Tomiyama, Akira Nagahara, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Koji Hatano, Atsunari Kawashima, Masashi Nakayama, Hitoshi Takayama, Yutaka Ono, Shingo Takada, Kensaku Nishimura, Kazutoshi Fujita, Ryoichi Imamura, Norio Nonomura","doi":"10.1007/s10147-026-03185-x","DOIUrl":"https://doi.org/10.1007/s10147-026-03185-x","url":null,"abstract":"<p><strong>Background: </strong>The efficacy of second-line cabozantinib following first-line immune checkpoint inhibitor (ICI)-based combinations, particularly after pembrolizumab plus lenvatinib (Pem + Len), remains uncharacterized. We evaluated real-world outcomes in patients with metastatic renal cell carcinoma (mRCC).</p><p><strong>Methods: </strong>This multicenter retrospective study included 96 mRCC patients who initiated second-line cabozantinib between 2021 and 2025, after first-line ipilimumab plus nivolumab (Ipi + Nivo; n = 36), avelumab or pembrolizumab plus axitinib (Ave/Pem + Axi; n = 30), or Pem + Len (n = 30). Endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) from cabozantinib initiation and from first-line therapy initiation, prognostic factors, and safety.</p><p><strong>Results: </strong>The overall ORR was 36% (Ipi + Nivo: 40%; Ave/Pem + Axi: 43%; Pem + Len: 23%). The median PFS from cabozantinib initiation was 9.4 months (Ipi + Nivo: 9.4; Ave/Pem + Axi: 15.9; Pem + Len: 8.7; P = 0.57), and the median OS was 25.5 months (P = 0.87). From first-line therapy initiation, the median PFS (27.1 months) and OS (42.2 months) did not differ significantly across groups (P = 0.70; P = 0.91). On multivariate analysis, only IMDC poor risk was independently associated with PFS. Grade  ≥ 3 treatment-related adverse events occurred in 34.4% of patients.</p><p><strong>Conclusion: </strong>Second-line cabozantinib provided meaningful efficacy across all approved first-line ICI-based combinations. Cumulative PFS from first-line therapy initiation was similar across regimens, although OS data for the Pem + Len group remain immature. Cabozantinib appears to represent a reasonable second-line option in the ICI era.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149136506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the implementation gap in hereditary cancer care for prostate cancer: a narrative review and Japanese environmental scan.","authors":"Eri Habano, Yusuke Sato, Miho Ogawa, Kousuke Watanabe, Nana Akiyama, Hyangri Chang, Eri Shijiki, Saeko Nagai, Akiko Kunita, Arisa Ueki, Hidenori Kage, Katsutoshi Oda","doi":"10.1007/s10147-026-03209-6","DOIUrl":"https://doi.org/10.1007/s10147-026-03209-6","url":null,"abstract":"<p><strong>Background: </strong>Genomic testing has become increasingly important in prostate cancer because BRCA1/2 and other genomic alterations can inform treatment selection and may indicate an underlying hereditary cancer syndrome. However, treatment-directed testing does not necessarily lead to genetic counseling, germline genetic testing, cascade testing, or familial risk management. Prostate cancer therefore presents a unique implementation challenge, particularly in tumor-first testing pathways.</p><p><strong>Methods: </strong>We conducted a narrative review of international literature on barriers to germline genetic testing and genetic counseling in prostate cancer, an environmental scan of publicly available Japanese sources, and targeted international comparisons of genetics specialist workforce and academic visibility. The findings were integrated into a logic model for hereditary cancer care implementation.</p><p><strong>Results: </strong>International evidence identified multilevel barriers, including variation in genetic knowledge and training opportunities among urologists, difficulty identifying eligible patients, communication and workflow constraints, limited access to genetics services, financial barriers, low patient awareness, and psychosocial and gender-related factors. The Japanese environmental scan indicated incomplete linkage from tumor genomic testing to genetic counseling, underrepresentation of urologists among genetics specialists, low academic visibility, and limited emphasis on familial risk management in patient materials, guidelines, and education. The logic model highlighted family history assessment, recognition of tumor-first genomic findings, embedded referral pathways, and patient-centered information support as key intervention points.</p><p><strong>Conclusions: </strong>The implementation gap reflects a structural disconnect between prostate cancer genomics and hereditary cancer care. Pathway redesign may help link tumor genomic testing with germline genetic testing and familial risk management.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for shorter recurrence-free survival in patients with resected biliary tract cancer treated with adjuvant S-1 chemotherapy.","authors":"Tomonao Taira, Mitsuhito Sasaki, Go Igarashi, Kanae Inoue, Taro Shibuki, Tomoyuki Satake, Masataka Amisaki, Hideaki Takahashi, Hiroshi Imaoka, Shuichi Mitsunaga, Masashi Kudo, Motokazu Sugimoto, Shin Kobayashi, Naoto Gotohda, Masafumi Ikeda","doi":"10.1007/s10147-026-03207-8","DOIUrl":"https://doi.org/10.1007/s10147-026-03207-8","url":null,"abstract":"<p><strong>Background: </strong>Adjuvant S-1 chemotherapy (ASC) has become the standard postoperative treatment for biliary tract cancer (BTC) in Japan following publication of the results of the ASCOT study, a recent nationwide randomized controlled study. However, recurrence remains common, and risk factors specific to patients treated with ASC are unclear.</p><p><strong>Methods: </strong>We retrospectively investigated the data of 56 patients with resected BTC at our institution between August 2021 and October 2023. Recurrence-free survival (RFS), overall survival (OS), and treatment safety were evaluated. Cox proportional hazards regression analysis was performed to identify the risk factors for shorter RFS.</p><p><strong>Results: </strong>Over a median follow-up of 22.6 months, 15 patients (26.8%) developed recurrence. The 12- and 24-month RFS rates were 84.8% and 71.6%, respectively, and the 12- and 24-month OS rates were 92.4% and 85.7%, respectively. Both univariate and multivariate analyses identified poorly differentiated tumor histology as a significant risk factor for shorter RFS. In addition, univariate analysis, but not multivariate analysis, also identified elevated pre-ASC serum CA19-9 levels (≥ 37 U/mL) as a significant risk factor for shorter RFS. Adverse events of ≥ grade 3 occurred in 3.6% of patients receiving ASC.</p><p><strong>Conclusions: </strong>Poorly differentiated tumor histology may be a risk factor for shorter RFS in patients with resected BTC treated with ASC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics, anatomical distribution, and diagnostic patterns of simple bone cysts in Japan: an analysis of the Japanese Bone and Soft Tissue Tumor registry.","authors":"Akihiko Takeuchi, Akira Kido, Akira Ogose, Kazu Matsumoto, Daisuke Kobayashi, Kota Watanabe, Michio Ozeki, Hiroshi Furukawa, Satoru Demura, Hiroyuki Tsuchiya, Akira Kawai, Yoshihiro Nishida","doi":"10.1007/s10147-026-03215-8","DOIUrl":"https://doi.org/10.1007/s10147-026-03215-8","url":null,"abstract":"<p><strong>Background: </strong>Simple bone cysts are benign cystic bone lesions that occur predominantly in children and adolescents, although they might occur in all ages. Previous studies have described clinical features and treatment options; however, large-scale epidemiological data from Japan are limited. We aimed to investigate the clinical characteristics, anatomical distribution, diagnostic patterns, and initial treatment tendencies of simple bone cysts in Japan using data from the Japanese Bone and Soft Tissue Tumor (BSTT) registry and a nationwide institutional survey.</p><p><strong>Methods: </strong>We performed a retrospective analysis using the BSTT registry maintained by the Musculoskeletal Tumor Committee of the Japanese Orthopedic Association. Patients diagnosed with simple bone cysts between 2006 and 2019 were included. Age at diagnosis, tumor location, method of diagnosis, presence of pathological fractures at presentation, and treatment patterns were analyzed.</p><p><strong>Results: </strong>Overall, 3164 patients with simple bone cysts were identified in the registry. The mean age at diagnosis was 22.4 years (range, 0-89 years). Notably, 1663 (52.6%) patients were pathologically confirmed and 1501 (47.4%) were clinically diagnosed without histological confirmation. The humerus was the most common tumor location (910 cases, 28.8%), followed by calcaneus (803 cases, 25.4%), and femur (682 cases, 21.6%). Surgical treatment was performed in 1480 patients.</p><p><strong>Conclusion: </strong>This nationwide registry-based study provided an overview of the clinical characteristics, anatomical distribution, diagnostic patterns, and treatment strategies for simple bone cysts in Japan. Diagnostic methods and treatment strategies differed according to patient age, and surgeries were performed more frequently for long-bone lesions than for lesions at other anatomical sites.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}